Medical therapy of neurocardiogenic syncope

Cardiology Clinics

Volumn 19, Issue 2, 2001, Pages 203-213

  Cadman, Christopher S ^b  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; ESMOLOL; FLUDROCORTISONE; ISOPRENALINE; METOPROLOL; MIDODRINE; MINERALOCORTICOID; PROPANTHELINE BROMIDE; PROPRANOLOL DERIVATIVE; SCOPOLAMINE; SEROTONIN UPTAKE INHIBITOR; SODIUM CHLORIDE; THEOPHYLLINE;

ACNE; BRADYCARDIA; DEPRESSION; DIAPHORESIS; EDEMA; HEART STROKE VOLUME; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; INCIDENCE; MECHANORECEPTOR; NAUSEA; PRESSORECEPTOR; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW; SYNCOPE; TILT TABLE TEST; VASOCONSTRICTION; VASODILATATION; VERTIGO; YAWNING;

EID: 0034981698     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8651(05)70208-3     Document Type: Article

References (80)

1. Neurocardiogenic syncope
2. Reflex control of the peripheral circulation
3. The usefulness of head-up tilt testing and hemodynamic investigations in the workup of syncope of unknown origin
4. Provocation of bradycardia and hypotension by isoproerenol and upright posture in patients with unexplained syncope
5. Vasodepressor syncope: Diagnosis and management
6. Tilt table testing for assessing syncope
7. Malignant vasovagal syncope: A randomised trial of metoprolol and clonidine
8. Reproducibility of a positive passive upright tilt test at a seven-day interval in patients with syncope
9. Panel consensus: Putting it together: A new treatment algorithm for vasovagal syncope and related disorders
10. Non-reproducibility of vasodepressor responses during upright tilt table testing performed on different days
11. Pharmacologic approaches to therapy for vasovagal syncope
12. Reproducibility of head-up tilt-table testing for eliciting susceptibility to neurally mediated syncope in patients without structural heart disease
13. Vasovagal syncope: Management with propantheline bromide
14. Acute and long-term beta-adrenergic blockade for patients with neurocardiogenic syncope
15. Salt supplement increases plasma volume and orthostatic tolerance in patients with unexplained syncope
16. A randomized trial of medical therapy in "Malignant Vasovagal Syndrome" or "Neurally-mediated Bradycardia/Hypotension Syndrome"
17. Vasovagal reactions may occur after orthoptic heart transplantation
18. Re-initiation of the vasovagal syndrome by adenosine 5′ triphosphate test: Assessment of the best therapy
19. Effects of paroxetine hydrochloride, a selective serotonin reuptake inhibitor, on refractory vasovagal syncope: A randomized, double-blind, placebo-controlled study
20. Prevention of neurally-mediated syncope by selective β-1 adenoceptor blockade
21. Pathophysiology and differential diagnosis of neurocardiogenic syncope
22. Neurocardiogenic syncope
23. Serotonin and syncope: An emerging connection?
24. The use of methylphenidate in the treatment of refractory neurocardiogenic syncope
25. Response of normal subjects during 80° head upright tilt table testing with and without low dose isoproterenol infusion
26. Use of sertraline hydrochloride in the treatment of refractory neurocardiogenic syncope in children and adolescents
27. Utility of upright tilt-table testing in the evaluation and management of syncope of unknown origin
28. The use of head-upright tilt testing in the evaluation and management of syncope in children and adolescents
29. Head-upright tilt-table testing in evaluation and management of the malignant vasovagal syndrome
30. Tilt table testing in the evaluation and management of athletes with recurrent exercise-induced syncope
31. Usefulness of fluoxetine hydrochloride for prevention of resistant upright tilt induced syncope
32. Reproducibility of head upright tilt table test results in patients with syncope
33. Syncopal disorders
34. 1B autoreceptor blocking properties the β adrenoceptor antagonist (-) penbutolol
35. Efficacy of oral ephedrine sulfate in preventing neurocardiogenic syncope
36. Evaluation and management of the patient with syncope
37. Upright tilt testing in evaluating syncope: A comprehensive literature review
38. Low dose disopyramide often fails to prevent neurogenic syncope head-up tilt testing
39. Head up tilt: A useful test for investigating unexplained syncope
40. Pathophysiological aspects of neurocardiogenic syncope: Current concepts and new perspectives
41. Review of the role of the central serotonergic neuronal system in blood pressure regulation
42. Syncope: Pathophysiology, diagnosis, and pharmacotherapy
43. Usefulness of transdermal scopolamine for vasovagal syncope
44. Absence of tachycardia during tilt test predicts failure of β-blocker therapy in patients with neurocardiogenic syncope
45. A lecture on vasovagal syncope and the carotid sinus mechanism
46. Differential therapeutic responses of patients with isoproterenol-dependent and isoproterenol-independent vasodepressor syncope
47. Syncope in an elderly, institutionalized population: Prevalence, incidence, and associated risk
48. Randomized double-blind, placebo-controlled trial of oral atenolol in patients with unexplained syncope and positive upright tilt table test results
49. The Bezold-Jarisch reflex revistited: Clinical implications of inhibitory reflexes originating in the heart
50. Increased vagal tone as an isolated finding in patients undergoing electrophysiologic testing for recurrent syncope: Response to long term anticholinergic agents
51. Mechanisms of tilt table induced hypotension and bradycardia in patients with neurally mediated syncope
52. Usefulness of disopyramide for prevention of upright tilt-induced hypotension-bradycardia
53. Pathophysiologic basis for vasodepressor syncope
54. A placebo-controlled trial of intravenous and oral disopyramide for prevention of neurally mediated syncope induced by head-up tilt
55. Limitations of head-up tilt test for evaluating the efficacy of therapeutic interventions in patients with vasovagal syncope: Results of a controlled study of etilefrine versus placebo
56. Efficacy of different treatment strategies for neurocardiogenic syncope
57. The autonomic and hemodynamic effects of oral theophylline in patients with vasodepressor syncope
58. Mechanisms of heart rate and arterial blood pressure control: Implications for the pathophysiology of neurocardiogenic syncope
59. Effects of etilefrine in preventing syncopal recurrence in patients with vasovagal syncope: A double-blind, randomized, placebo-controlled trial
60. Neural control mechanisms and vasovagal syncope
61. Epidemiologic features of isolated syncope: The Framingham study
62. Randomized comparison of atenolol and fludrocortisone acetate in the treatment of pediatric neurally mediated syncope
63. Echocardiographic demonstration of decreased left ventricular dimensions and vigorous myocardial contraction during syncope induced by head-up tilt test
64. Effect of blocker on time to first syncope recurrence in patients after a positive isoproterenol tilt table test
65. Risk factors for syncope recurrence after a positive tilt-table test in patients with syncope
66. Changes in renal sympathetic outflow during hypotensive hemorrhage in rats
67. Unexplained syncope evaluated by electrophysiologic studies and head-up tilt test
68. Neurocardiogenic syncope: Diagnosis, mechanisms, and treatment
69. Sequential catecholamine changes during upright tilt: Possible hormonal mechanisms responsible for pathogenesis of neurocardiogenic syncope
70. Efficacy of midodrine hydrochloride in neurocardiogenic syncope refractory to standard therapy
71. Use of intravenous esmolol to predict efficacy of oral β-adrenergic blocker therapy in patients with neurocardiogenic syncope
72. Efficacy of α-adrenergic agonist therapy for prevention of pediatric neurocardiogenic syncope
73. Beneficial effects of dextro-amphetamine in the treatment of vasodepressor syncope
74. Effect of d- and l-propranolol on the discharge of cardiac vagal C fibers
75. Reflex inhibition of renal sympathetic nerve activity during myocardial ischemia mediated by left ventricular receptors with vagal afferents in dogs
76. Midodrine: A role in the management of neurocardiogenic syncope
77. Efficacy of intravenous granisetron in suppressing the bradycardia and hypotension associated with a rabbit model of the Benzold-Jerisch reflex
78. A review of pathophysiology and therapy of patients with vasovagal syncope
79. Effect of the serotonin receptor antagonist granisetron on neurally mediated syncope
80. Clinical efficacy of propantheline bromide in neurocardiogenic syncope: Pharmacodynamic implications